Jeffrey G. Lamothe - Aug 8, 2024 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
EVP, COO
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Aug 8, 2024
Transactions value $
$0
Form type
4
Date filed
8/9/2024, 04:33 PM
Previous filing
Jul 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +42 +4.93% 894 Aug 8, 2024 Direct F1
transaction APVO Common Stock Options Exercise +272 +30.43% 1.17K Aug 8, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -42 -50.6% $0.00 41 Aug 8, 2024 Common Stock 42 Direct F1, F2
transaction APVO Restricted Stock Unit Options Exercise $0 -272 -100% $0.00* 0 Aug 8, 2024 Common Stock 272 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On August 9, 2022, the reporting person was granted 5,500 (125 post-split) RSUs, vesting in three approximately equal annual installments beginning on August 8, 2023.
F3 On August 9, 2022, the reporting person was granted 23,958 (544 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023.